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bstract
A case of Hepatitis A occurred in a traveller in spite of a complete course of immunization with a combined HAV and HBV vaccine [Taliani
, Sbaragli S, Bartoloni A, Santini MG, Tozzi A, Paradisi F. Hepatitis A vaccine failure: how to treat the threat. Vaccine 2003;21(31):4505–6].
retrospective study was performed to evaluate whether the failure was primary or could be attributed to a specific lot of vaccine or to its
nadequate handling and/or storage. Two distinct populations of vaccinees were selected in a 1:2 proportion. The case group (N = 31) included
ubjects who were vaccinated in the same period and with the same lot and batch of vaccine as the case. The control group (N = 62) included
ubjects who received different lot and batch of the same vaccine as the case group. A persisting antibody response to HAV vaccine was found
mong all subjects (anti-HAV >20 mIU/ml). The overall anti-HBs seropositivity rate (anti-HBs >10 mIU/ml) was 74%, without significant
ifference between the case (77%) and the control group (73%; P > 0.05). The reported Hepatitis A case can be attributed to a rare primary
accine failure rather than to inefficacy of a specific lot of vaccine or to inappropriate vaccine handling or storage. Our study supports the
ndications for use of combined Hepatitis A + B immunization in travellers at risk for both infections, but stresses the need for information on
orrect hygienic behaviours while abroad.
2006 Elsevier Ltd. All rights reserved.
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. Introduction
Hepatitis A infection has a worldwide diffusion and rep-
esents a relevant public health concern. It is well known
hat one of the major risk factor for acquiring Hepatitis A
nfection is represented by travelling to highly endemic areas
2–4]. Although general hygienic measures play a basic role
or prevention, the protection conferred by vaccination is of
ajor importance and immunization against Hepatitis A is
∗ Corresponding author at: Department of Public Health, University of
lorence, Viale Morgagni, 48, 50134 Firenze, Italy. Tel.: +39 055 4598511;
ax: +39 055 4598935.
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ecommended for those persons who travel to areas of high
r intermediate endemicity [5,6].
The existence of a combined Hepatitis A and Hepatitis
vaccine, approved since 1997 in Italy for both adults and
hildren and since 2001 [7] by the US Food and Drug Admin-
stration (FDA) for persons aged 18 years or older (≥16 years
n Europe) [8], gives the opportunity to protect against both
epatitis infections with a reduced total number of injections
hich ensures a higher compliance towards immunization
ractices. In addition, it implies minimal loss of time for
ravellers and health care workers (HCWs) and it providespersistent immunity [9,10] comparable to the protection
btained from monovalent vaccines given separately.
Despite high vaccine effectiveness, at least four cases of
rimary vaccine failure were described in the international
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iterature [1,11,12]. One of these cases occurred in a man who
ad travelled to an endemic area 2 years after completion of
he vaccination course with three doses of combined HAV
nd HBV vaccine [1]. This case prompted us to perform a
etrospective case-control study in order to examine whether
he failure could be attributed to the use of a specific lot
f vaccine or to inadequate handling and/or storage of the
accine at the vaccination Centre.
. Materials and methods
A retrospective study was performed to evaluate whether
he failure was primary or could be attributed to a specific lot
f vaccine or to its inadequate handling and/or storage.
All subjects included in the study were vaccinated at the
Centre for Travel Medicine and Migrations” of the Public
ealth and Hygiene Service, Local Health Agency, Florence.
he selection of subjects (case group and control group)
ccording to the inclusion criteria was performed through
he database currently employed for the management of the
accination service.
The first step was to identify the batches of HAV/HBV
accine (Twinrix®, GlaxoSmithKline, Rixensart, Belgium)
dministered to the vaccine failure case. The first two doses
elonged to the same batch (HAB 154 C6 – Expiry date: 30
ovember 2001) while the third dose belonged to another
atch (HAB 168 B – Expiry date: 31 May 2002). The sub-
ect received a complete course of three doses, starting in
ovember 1999 and he completed the vaccination course in
uly 2000.
In order to evaluate the immunogenicity of the batches
sed for the case, we recalled people who had been immu-
w
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Fig. 1. Case and control inclusion criteria flow-chart. The batches4 (2006) 6053–6057
ized in the same period (±45 days), with the same batches
nd with an identical schedule.
The control group consisted of vaccinees who had been
dministered different batches of the same vaccine. Neces-
arily, the study design implied that controls had received the
accine in a different period. The chosen period corresponded
o 12 months before vaccination of the Hepatitis A case.
.1. Case group inclusion
Subjects of the so-called ‘case group’ were chosen among
population of 274 vaccinees who received the first dose
etween October 1999 and December 1999 (first dose of the
ase ±45 days). Among these, 195 subjects received the sec-
nd dose between November 1999 and January 2000 (second
ose of the case ±45 days), and 115 subjects received the
hird dose between June 2000 and August 2000 (third dose
f the case ±45 days). Among these 115 identified subjects,
e randomly selected 40 people (35% of the sample). Nine
accinees refused to participate in the study, thus we finally
btained a serum sample from 31 randomly selected subjects
hich corresponded to 1/3 of the identified vaccinees (Fig. 1).
.2. Controls inclusion
The rationale for choosing the control group was to assess
he immunogenicity of a different batch of the vaccine admin-
stered in the same Centre with the same schedule as the
epatitis A case. We identified two batches of Twinrix® that
ere used 12 months before the batches administered to the
ase and we chose controls among people who received the
rst two doses with the first identified batch (HAB 123 B6 –
xpiry date: 31 January 1999) and the third dose with the sec-
of Twinrix® administered to the subjects are also reported.
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Table 1
Demographic characteristics of case group and control group (n, number of
subjects)
Group n Mean
age
(years)
Age
range
(years)
Case
Female 14 41.6 24–62 ]
Male 17 39.5 25–64 P = 0.6826
Total 31 40.4 24–64
Control
⎤
⎥⎦P = 0.0876
Female 31 34.8 20–63 ]
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Stratification of anti-HBs seropositivity rate by age
showed no difference within and between groups (Table 3).
Geometric mean titres (GMTs) of anti-HBs and 95%
confidence intervals (95% CI) for case and control groups
Table 2
Seropositivity rate (SR) of anti-HAV and anti-HBs (n, number of subjects)
Group n Anti-HAV
positive
Anti-HBs
positive
n SR
(%)
n SR
(%)
Case
Female 14 14 100 14 100 ]
Male 17 17 100 10 58.8 P = 0.5651
Total 31 31 100 24 77.4
Control
⎤
⎥P = 0.6151P. Bonanni et al. / Va
nd batch (HAB 131 B6 – Expiry date 31 October 1999). A
opulation of 373 people who received the first dose between
ay 1998 and June 1998 was identified. Among these sub-
ects, 202 vaccinees were immunized with the second dose
month later and received the third dose after 6 months. Out
f this sample we randomly selected 62 subjects (Fig. 1).
All subjects were contacted by phone. Written, informed
onsent was obtained from those vaccinees who accepted to
articipate in the study and to undergo blood testing. The
lood samples, collected from September 2002 to March
003, were frozen, stored in aliquots at −20 ◦C and tested
imultaneously.
. Laboratory methods and statistics
Qualitative/quantitative determinations of antibodies to
AV (ETI-AB-HAVK-3), to Hepatitis B core (anti-HBc,
TI-AB-COREK-2) and to Hepatitis B surface (anti-HBs,
TI-AB-AUK-3) antigens were performed with DiaSorin
its (DiaSorin s.r.l. Saluggia, Vercelli, Italy). All the
ssays are based on the ELISA technique (enzyme-linked
mmunosorbent assay). In particular, the method for quanti-
ative anti-HAV determination is a competitive binding assay,
he method for quantitative determination of anti-HBs is a
irect, non-competitive sandwich assay, while the method for
ualitative anti-HBc determination is a simultaneous compet-
tive assay.
Samples with a concentration of anti-HAV greater than
0 mIU/ml were considered positive. Due to the objective
f the study, no further determination of precise anti-HAV
itre was performed (upper detection limit of the assay:
0 mIU/ml).
The cut-off value for anti-HBs was 10 mIU/ml. Only pos-
tive titres of anti-HBs (≥10 mIU/ml) were used in the cal-
ulation of the geometric mean titres (GMTs).
The GraphPad InStat Software (GraphPad Software Inc.,
an Diego, California) was used for statistical analysis of
ata. InStat gives descriptive statistics as mean, standard
eviation, range and confidence interval for each group of
alues considered. The unpaired t-test was applied to com-
are the mean age of the two groups, assuming that data are
ampled from Gaussian populations and that the two popu-
ations have the same variance (and thus the same standard
eviation).
. Results
The demographic characteristics of the two groups are
eported in Table 1.
There were no statistically significant differences in the
omposition of the two groups as far as age or gender were
oncerned (P > 0.05 in both cases).
Due to the study design, the mean interval, in months,
etween administration of the last vaccine dose and anti-Male 31 37.0 24–60 P = 0.4330
Total 62 35.9 20–63
ody testing was significantly longer among the control
45.2 ± 1.3) compared to the case group (28.2 ± 1.8).
.1. Anti-HAV
Determination of anti-HAV antibody titre showed that
ll vaccinees in both groups were anti-HAV positive
≥20 mIU/ml), which indicates a 100% rate of response to
he vaccine. All serum samples belonging to the case group,
nd all but two samples in the control group (titres of anti-
AV: 50 and 64 mIU/ml, respectively) had anti-HAV titres
70 mIU/ml (Table 2).
.2. Anti-HBV
The rates of anti-HBs ≥10 mIU/ml in the case and
he control group were 77.4% and 72.6%, respectively
P = 0.615). Females were more frequently positive com-
ared to males, among both the case and the control group,
lthough the difference was significant only among controls,
robably due to the small size of the case group (Table 2).⎦
Female 31 31 100 28 90.3 ]
Male 31 31 100 17 54.8 P = 0.0017
Total 62 62 100 45 72.6
6056 P. Bonanni et al. / Vaccine 2
Table 3
Seropositivity rate (SR) of anti-HBs stratified by age group (n, number of
subjects)
Case Control
n Anti-HBs+ SR (%) n Anti-HBs+ SR (%)
Age (years)
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≥40 13 10 77 20 14 70
tratified by gender and age are reported in Table 4. Titres
f anti-HBs in women were higher than in men, but this dif-
erence was significant neither in the case group (P = 0.917)
or in the control group (P = 0.1978). Besides, we compared
MT of cases and controls by age and even in this case no
tatistically difference was found.
All subjects belonging to the case group were negative
o antibodies against HBc, while in the control group a
2-year-old-woman (anti-HBs titre 16,500 mIU/ml) and a
9-year-old-man (anti-HBs titre 59 mIU/ml) resulted anti-
Bc positive (3.2%), which suggests the occurrence of HBV
nfection. We do not know the serologic profile of these two
ubjects at the time of vaccine administration, therefore we
re not able to firmly discriminate between a condition of
accine failure followed by HBV infection or vaccination of
wo subject who had spontaneously cleared HBV infection
efore vaccination.
. Discussion
It is estimated that each year people who travel from Italy
o foreign countries are about 18 million [13] and many of
hem leave to tropical areas where Hepatitis A and B are
ndemic.
Recently, an Italian epidemiological study indicated that
mong 17,039 cases of acute Hepatitis A observed during the
eriod 1996–2000, 1519 (15.5%) reported recent travel to an
ndemic area as a risk factor, with an OR of 4.11 (95% CI
.53–4.79) which was considerably higher than the OR of
ny other risk factor [14]. Consequently, vaccination against
i
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t
able 4
eometric mean titres (GMTs) of anti-HBs and 95% confidence intervals (95% C
ubjects)
Case
n GMT (95% CI)
ender
Female 14 145.83 (62.66–339.63)
Male 10 136.66 (45.39–411.15)
ge (years)
<40 14 164.53 (76.91–352.37)
≥40 10 115.43 (34.28–389.05)
otal 24 141.94 (76.56–263.63)4 (2006) 6053–6057
epatitis A infection is strongly recommended for travellers
o endemic areas.
Our study was prompted by the observation of a vaccine
ailure represented by acute Hepatitis A in spite of a cor-
ect immunization scheme in a traveller returning from a
yperendemic country. By examining the seropositivity rates
btained in 31 vaccinees after administration of the same
accine lot and batch during an identical time interval as the
ase, we found that the combined HAV and HBV vaccine
nduced a 100% immunization rate against HAV. There-
ore, the occurrence of the failure was not attributable to the
accine (production, storage, administration), but was most
robably due to an episode of individual non-responsiveness
o HAV immunization. This hypothesis was reinforced by
he observation that also a different lot and batch of the same
accine administered to control subjects induced an immu-
ization rate of 100%. Seroprotection against HAV was fairly
ell detectable 32 and 48 months after administration of the
ast vaccine dose in the case and the control groups, respec-
ively, with anti-HAV levels clearly above the threshold level
f 20 mIU/ml in all vaccinees. These results are in accordance
ith previous studies reporting that protective levels of anti-
AV are maintained in all responder subjects 48 months after
ompletion of vaccination course [15].
On the other hand, in our group of vaccinees, the
dministration of the combined HAV and HBV vaccine gave
n anti-HBs seropositivity level well under 100% after the
ame time intervals, most appreciable among males. The
ower rate of anti-HBs seropositivity among males after a
orrect immunization course suggests either a lower initial
eroconversion rate and/or a more rapid loss of antibodies
ompared to females. This was previously reported in the
nternational literature [16], but the large difference recorded
n this study is probably due to the small sample size.
urthermore, a lower number of anti-HBs reactive subjects
oes not necessarily mean lack of protection against HBV
nfection in those subjects, because Hepatitis B vaccine
nduces a strong immunologic memory which is activated
y the contact with the virus or a booster dose even after 10
ears from primary vaccination [17]. It is interesting to note
hat we did not find any significant difference of response
I) for case and control groups stratified by gender and age (n, number of
Control
n GMT (95% CI)
28 342.86 (181.13–648.63)
17 179.33 (80.54–399.02)
31 305.9 (162.93–574.12)
14 200.88 (88.72–454.99)
45 268.40 (164.82–437.52)
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o HBV vaccine according to age. This result is in contrast
ith what is reported in a retrospective study showing that
8 months after vaccination with a combined HAV and HBV
accine, the rate of anti-HBs positivity was significantly
igher in people aged less than 40 compared to older people
18], the most probable explanation for this difference being
elated to the small size of our study population.
In conclusion, the present study showed that Twinrix® pro-
ides long-lasting antibody responses to HAV antigen among
dults aged between 20 and 64 years, while low anti-HBs
eropositivity rates detected in males in this study should
e interpreted with caution and need further investigations.
lthough rare, primary vaccine failure to HAV vaccine is
possible event probably linked to individual inability to
ount an appropriate, specific immune response to the vac-
ine components. Thus, vaccination may not be synonymous
o absolute guarantee of protection and correct counselling,
onsisting in the recommendation of continuous adherence to
he universal safety measures for the prevention of infections,
hould be strongly advised also to vaccinated people.
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